Utilization of LABAs versus SABAs in Albanian Insured Outpatients with COPD during 2008-2012

Abstract

Introduction: Inhaled ?2-agonists as bronchodilators are commonly used in Chronic Obstructive Pulmonary Disease (COPD). These drugs can be either short-acting (SABA) or long-acting (LABA). The aim of this retrospective study is to evaluate the use patterns of inhaled LABAs versus inhaled SABAs reimbursed in Albania during 2008-2012 for ambulatory COPD treatment. Methods: Data on analyzed drugs for COPD treatment were taken from Health Insurance Institute database. ATC/DDD methodology was used to quantify the consumption of inhaled ?2-agonists in DDD/1000 inhabitants/day and the results were expressed as percentage of annual drug use. All the data are calculated with Microsoft Office Excel program. Results: The utilization ratio of LABAs to SABAs was: 4:96 in 2008, 9.5:90.5 in 2009, 25:75 in 2010, 34:66 in 2011 and 45:55 in 2012 respectively. During 2009-2012 the use of LABAs was increased, especially when they were in combination with inhaled corticosteroids (ICS). These combinations represented 5%, 18%, 24% and 23% of total annual consumption during four years respectively. In 2012 Salmeterol plus Fluticasone was the most used combination and Indicaterol was the most used among plain LABAs. Conclusion: The use of inhaled LABAs continually is increased versus SABAs ones for COPD treatment in Albanian insured outpatients during 2008-2012. These changes refered to the international guidelines wich recommend SABAs for as-needed symptom relief and LABAs as long-term maintenance therapies. In addition LABA/ICS combinations have greater efficacy than either of its components used alone.

DOI: 10.5901/mjss.2013.v4n9p573